Fully Automated Gram Stain Launched
|
By LabMedica International staff writers Posted on 30 Oct 2013 |
|
Image: Gram positive and Gram-negative bacteria with green counterstain stained using VENTANA Gram Staining Kit on the BenchMark Special Stains automated staining platform (Photo courtesy of Ventana Medical systems, Inc.).
A fully automated Gram Stain Kit has been launched globally on the BenchMark Special Stains platform.
The Gram Staining Kit aids pathologists in the most basic classification of bacteria into Gram-positive and Gram-negative bacteria in fixed tissue samples. Gram stain classification is clinically useful as it provides an initial indication of the nature of a patient's infection.
The Gram stain is part of a family of histochemical special stains that many laboratories around the world still run manually today. In automating the stain, Ventana (VMSI; Tucson, AZ, USA) offers an efficient and automated method to perform this technically challenging assay, enabling them to achieve increased productivity, consistency, and testing quality.
"Tissue diagnostics play a critical role in enabling accurate diagnosis and treatment decisions for cancer patients. Ventana provides laboratories, pathologists, and their patients with novel assays, and the company is empowering its customers to achieve greater efficiencies by automating common, yet labor-intensive tests like the Gram stain," says Mara G. Aspinall, president, Ventana Medical Systems, Inc.
The Gram Staining kit is the newest addition to the Ventana product offerings on the fully automated BenchMark Special Stains platform launched in mid-2012. The kit offers two counterstain options and testing protocol flexibility to meet pathologists' individual preferences.
"The new Gram Staining Kit will provide our customers visual consistency and clarity rarely achieved with manual Gram staining protocols. Our commitment to quality and advancing diagnostic consistency through world-class automation shines with this new product," said Adrian Ralph, vice president, Primary Staining, Ventana Medical Systems, Inc.
The VENTANA Gram Stain Kit is being launched as a US Class I exempt/ CE-IVD product.
Related Links:
Ventana
The Gram Staining Kit aids pathologists in the most basic classification of bacteria into Gram-positive and Gram-negative bacteria in fixed tissue samples. Gram stain classification is clinically useful as it provides an initial indication of the nature of a patient's infection.
The Gram stain is part of a family of histochemical special stains that many laboratories around the world still run manually today. In automating the stain, Ventana (VMSI; Tucson, AZ, USA) offers an efficient and automated method to perform this technically challenging assay, enabling them to achieve increased productivity, consistency, and testing quality.
"Tissue diagnostics play a critical role in enabling accurate diagnosis and treatment decisions for cancer patients. Ventana provides laboratories, pathologists, and their patients with novel assays, and the company is empowering its customers to achieve greater efficiencies by automating common, yet labor-intensive tests like the Gram stain," says Mara G. Aspinall, president, Ventana Medical Systems, Inc.
The Gram Staining kit is the newest addition to the Ventana product offerings on the fully automated BenchMark Special Stains platform launched in mid-2012. The kit offers two counterstain options and testing protocol flexibility to meet pathologists' individual preferences.
"The new Gram Staining Kit will provide our customers visual consistency and clarity rarely achieved with manual Gram staining protocols. Our commitment to quality and advancing diagnostic consistency through world-class automation shines with this new product," said Adrian Ralph, vice president, Primary Staining, Ventana Medical Systems, Inc.
The VENTANA Gram Stain Kit is being launched as a US Class I exempt/ CE-IVD product.
Related Links:
Ventana
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Uric Acid and Blood Glucose Meter
URIT-10
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
Latest Pathology News
- Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Molecular Diagnostics
view channel
Cheap Cell-Free DNA Based Test Accurately Predicts Preterm Birth
Preterm birth (PTB) occurs in around 11% of all births globally, leading to considerable morbidity and mortality for both mothers and their newborns. Identifying pregnancies at risk of PTB early in gestation... Read more
RNA Blood Test Detects Cancers and Resistance to Treatment
A newly developed blood test offers the ability to detect cancer, understand how cancer resists treatments, and assess tissue damage from non-cancerous conditions. This innovative test, created by researchers... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Technology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
